PredictAD

FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER'S DISEASE

Coordinatore	TEKNOLOGIAN TUTKIMUSKESKUS VTT    more  Organization address address: Tekniikankatu 1 city: Tampere postcode: 33101 contact info Titolo: Ms. Nome: Jaana Cognome: Heino Email: send email Telefono: +358 20 7223301 Fax: +358 20 7223499
Nazionalità Coordinatore	Finland [FI]
Totale costo	3˙908˙233 €
EC contributo	2˙891˙526 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2007-2
Funding Scheme	CP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-06-01   -   2011-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	TEKNOLOGIAN TUTKIMUSKESKUS VTT  Organization address address: Tekniikankatu 1 city: Tampere postcode: 33101 contact info Titolo: Ms. Nome: Jaana Cognome: Heino Email: send email Telefono: +358 20 7223301 Fax: +358 20 7223499	FI (Tampere)	coordinator	0.00
2	Nome Ente NON disponibile  Organization address address: YLIOPISTONRANTA city: Kuopio postcode: 70211 contact info Titolo: Prof. Nome: Hilkka Cognome: Soininen Email: send email Telefono: +358 17 173012 Fax: +358 17 173019	FI (Kuopio)	participant	0.00
3	GE HEALTHCARE LIMITED  Organization address address: AMERSHAM PLACE city: LITTLE CHALFONT postcode: HP7 9NA contact info Titolo: Dr. Nome: Lennart Cognome: Thurfjell Email: send email Telefono: +46 730 699057 Fax: +46 18 666819	UK (LITTLE CHALFONT)	participant	0.00
4	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: Exhibition Road, South Kensington Campus city: LONDON postcode: SW7 2AZ contact info Titolo: Mr. Nome: Shaun Cognome: Power Email: send email Telefono: +44 207 5948773 Fax: +44 207 5948609	UK (LONDON)	participant	0.00
5	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag city: STOCKHOLM postcode: 17177 contact info Titolo: Ms. Nome: Anneli Cognome: Svarén Email: send email Telefono: +46 8 524 876 01 Fax: +46 8 736 04 39	SE (STOCKHOLM)	participant	0.00
6	NEXSTIM OY*  Organization address address: ELIMAENKATU 9 B city: HELSINKI postcode: 510 contact info Titolo: Dr. Nome: Jarmo Cognome: Laine Email: send email Telefono: +358 50 374 2748 Fax: +358 9 2727 1717	FI (HELSINKI)	participant	0.00
7	REGION HOVEDSTADEN  Organization address address: KONGENS VAENGE city: HILLEROD postcode: 3400 contact info Titolo: Ms. Nome: Jette Cognome: Rasmussen Email: send email Telefono: +45 35 453572 Fax: +45 35 452626	DK (HILLEROD)	participant	0.00
8	UNIVERSITA DEGLI STUDI DI MILANO  Organization address address: Via Festa Del Perdono city: MILANO postcode: 20122 contact info Titolo: Prof. Nome: Mauro Cognome: Moroni Email: send email Telefono: +39 02 50319759 Fax: +39 02 50319758	IT (MILANO)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.nThe objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.nBy reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.